GENELUX Corp
GNLXAs of the close on Sep 25, 2026
Price
$2.48
Market cap
$112M
P/E (diluted TTM)
—
The fourth quarter's per-share figure could not be confirmed from the annual report
EPS (TTM)
—
The fourth quarter's per-share figure could not be confirmed from the annual report
Dividend yield
—
Dividend records do not yet cover the latest payments
Figures shown here come from public SEC filings. Dates beside each section show the available history.
How GENELUX Corp Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: GENELUX Corp — 10-K filed Mar 19, 2026
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 4 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 18, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Align Financial, LLC | 2026-03-31 | 6,490 | $15.7K | SEC filing |
| WELLS FARGO & COMPANY/MN | 2026-03-31 | 2,235 | $5.41K | SEC filing |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 2026-03-31 | 41,000 | $105K | SEC filing |
| Stratos Wealth Partners, LTD. | 2026-03-31 | 12,745 | $30.8K | SEC filing |
| Prudent Man Investment Management, Inc. | 2026-03-31 | 660 | Not shown | SEC filing |
| HRT FINANCIAL LP | 2026-03-31 | 13,447 | Not shown | SEC filing |
| COMMONWEALTH EQUITY SERVICES, LLC | 2026-03-31 | 17,083 | $41.3K | SEC filing |
| GEODE CAPITAL MANAGEMENT, LLC | 2026-03-31 | 453,761 | $1.1M | SEC filing |
| MAI Capital Management | 2026-03-31 | 11,757 | $28.5K | SEC filing |
| LPL Financial LLC | 2026-03-31 | 139,041 | $336K | SEC filing |
| Apollon Wealth Management, LLC | 2026-03-31 | 18,784 | $45.5K | SEC filing |
| Strive Financial Group ,LLC | 2026-03-31 | 5,000 | $12K | SEC filing |
| XTX Topco Ltd | 2026-03-31 | 22,935 | $55.5K | SEC filing |
| INTEGRITY ALLIANCE, LLC. | 2026-03-31 | 15,052 | $36.4K | SEC filing |
| OMERS ADMINISTRATION Corp | 2026-03-31 | 17,600 | $42.6K | SEC filing |
| Creative Planning | 2026-03-31 | 45,572 | $110K | SEC filing |
| FMR LLC | 2026-03-31 | 903 | $2.19K | SEC filing |
| BROWN BROTHERS HARRIMAN & CO | 2026-03-31 | 1,350 | $3.27K | SEC filing |
| SteelPeak Wealth, LLC | 2026-03-31 | 60,895 | $147K | SEC filing |
| Blue Trust, Inc. | 2026-03-31 | 9,479 | $22.9K | SEC filing |
- Each value is checked against GENELUX Corp's share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the filed value is about 1,000 times too small for the share count at GENELUX Corp's share price.
- Value not shown for 1 row: the value per share could not be confirmed against the share prices on file from within three months of the report date.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- D.A. DAVIDSON & CO.: 21,779 shares reported 2025-12-31; 21,779 shares reported 2026-03-31.
- Provident Wealth Management, LLC: 155,670 shares reported 2025-12-31; 155,670 shares reported 2026-03-31.
- Falcon Wealth Planning: 63,185 shares reported 2025-12-31; 63,185 shares reported 2026-03-31.
- Caldwell Trust Co: 100 shares reported 2025-12-31; 100 shares reported 2026-03-31.
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC: 25,000 shares reported 2025-12-31; 25,000 shares reported 2026-03-31.
- One Capital Management, LLC: 30,883 shares reported 2025-12-31; 30,883 shares reported 2026-03-31.
- CENTAURUS FINANCIAL, INC.: 10,000 shares reported 2025-12-31; 10,000 shares reported 2026-03-31.
- JPMORGAN CHASE & CO: 26 shares reported 2025-12-31; 343 shares reported 2026-03-31.
- UBS Group AG: 47,360 shares reported 2025-12-31; 122,579 shares reported 2026-03-31.
- KWB Wealth: 23,327 shares reported 2025-12-31; 23,327 shares reported 2026-03-31.
- WOODWARD DIVERSIFIED CAPITAL, LLC: 1,932,711 shares reported 2025-12-31; 2,117,183 shares reported 2026-03-31.
- NORTHERN TRUST CORP: 142,838 shares reported 2025-12-31; 164,456 shares reported 2026-03-31.
Showing the 12 most recent filer reports.
38 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among GENELUX Corp's recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2024-09-13 · Szalay Aladar: Larger than 106 of the 115 other insider sales of Common Stock on file. SEC filing
- 2024-09-12 · Szalay Aladar: Larger than 104 of the 115 other insider sales of Common Stock on file. SEC filing
- 2024-09-03 · Szalay Aladar: Larger than 109 of the 115 other insider sales of Common Stock on file. SEC filing
- 2024-08-30 · Szalay Aladar: Larger than all 115 other insider sales of Common Stock on file. SEC filing
- 2024-08-29 · Szalay Aladar: Larger than 114 of the 115 other insider sales of Common Stock on file. SEC filing
- 2024-08-27 · Szalay Aladar: Larger than 112 of the 115 other insider sales of Common Stock on file. SEC filing
- 2024-08-23 · Szalay Aladar: Larger than 108 of the 115 other insider sales of Common Stock on file. SEC filing
- 2024-05-29 · Zindrick Thomas: Larger than all 8 other insider purchases of Common Stock on file. SEC filing
- 2024-05-29 · Zindrick Thomas (derivative): Larger than all 8 other insider purchases of Common Stock Warrant (Right to Buy) on file. SEC filing
- 2024-05-01 · Szalay Aladar: Larger than 105 of the 115 other insider sales of Common Stock on file. SEC filing
- 2024-04-16 · Szalay Aladar: Larger than 110 of the 115 other insider sales of Common Stock on file. SEC filing
- 2023-12-07 · Yu Yong: Larger than 107 of the 115 other insider sales of Common Stock on file. SEC filing
- 2023-10-23 · Szalay Aladar: Larger than 111 of the 115 other insider sales of Common Stock on file. SEC filing
- 2023-10-03 · Szalay Aladar: Larger than 113 of the 115 other insider sales of Common Stock on file. SEC filing
Independent insiders buying near the same time
- 2024-05-29–2024-05-29: 9 event(s) across 9 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing , filing , filing , filing )
- 2024-05-29–2024-05-29: 9 event(s) across 9 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing , filing , filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-03 | Smalling Ralph · Head of Regulatory | Common Stock | S — Open market or private sale | −192 | 2.93 | SEC filing |
| 2026-06-01 | Thomas John · Director | Common Stock | S — Open market or private sale | −10,000 | 2.98 | SEC filing |
| 2026-05-11 | Zindrick Thomas · President and CEO | Common Stock | S — Open market or private sale | −2,798 | 2.94 | SEC filing |
| 2026-05-11 | Smalling Ralph · Head of Regulatory | Common Stock | S — Open market or private sale | −270 | 2.98 | SEC filing |
| 2026-05-11 | Yu Yong · Chief Scientific Officer | Common Stock | S — Open market or private sale | −605 | 2.97 | SEC filing |
| 2026-05-11 | Cappello Joseph · Chief Technical Officer | Common Stock | S — Open market or private sale | −605 | 2.97 | SEC filing |
| 2026-03-25 | Smalling Ralph · Head of Regulatory | Common Stock | S — Open market or private sale | −240 | 2.51 | SEC filing |
| 2026-03-24 | Yu Yong · SVP, Clinical Development | Common Stock | S — Open market or private sale | −906 | 2.42 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-16 | Zindrick Thomas · President and CEO | Common Stock | A — Grant, award, or other acquisition | +730,601 | SEC filing |
| 2026-06-16 | Groen Eric · General Counsel | Common Stock | A — Grant, award, or other acquisition | +233,957 | SEC filing |
| 2026-06-16 | Thomas John · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +31,566 | SEC filing |
| 2026-06-16 | Pulisic Matthew · Chief Financial Officer | Common Stock | A — Grant, award, or other acquisition | +278,906 | SEC filing |
| 2026-06-16 | Yu Yong · Chief Scientific Officer | Common Stock | A — Grant, award, or other acquisition | +119,318 | SEC filing |
| 2026-06-16 | Thomas John · Director | Common Stock | A — Grant, award, or other acquisition | +28,409 | SEC filing |
| 2026-06-16 | Smither John W · Director | Common Stock | A — Grant, award, or other acquisition | +28,409 | SEC filing |
| 2026-06-16 | Tyree James L · Director | Common Stock | A — Grant, award, or other acquisition | +28,409 | SEC filing |
Showing 8 of 21 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2025-09-01 | Yu Yong · SVP, Clinical Development | Stock Option (Right to Buy) | D — Disposition to the issuer | −207,652 | SEC filing |
| 2025-09-01 | Zindrick Thomas · President and CEO | Stock Option (Right to Buy) | D — Disposition to the issuer | −925,000 | SEC filing |
| 2025-09-01 | Cappello Joseph · Chief Technical Officer | Stock Option (Right to Buy) | D — Disposition to the issuer | −13,333 | SEC filing |
| 2025-09-01 | Zindrick Thomas · President and CEO | Stock Option (Right to Buy) | D — Disposition to the issuer | −23,568 | SEC filing |
| 2025-09-01 | Cappello Joseph · Chief Technical Officer | Stock Option (Right to Buy) | D — Disposition to the issuer | −65,000 | SEC filing |
| 2025-09-01 | Yu Yong · SVP, Clinical Development | Stock Option (Right to Buy) | D — Disposition to the issuer | −65,000 | SEC filing |
| 2025-09-01 | Cappello Joseph · Chief Technical Officer | Stock Option (Right to Buy) | D — Disposition to the issuer | −16,666 | SEC filing |
| 2025-09-01 | Cappello Joseph · Chief Technical Officer | Stock Option (Right to Buy) | D — Disposition to the issuer | −80,000 | SEC filing |
Showing 8 of 10 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.